Manufacturers of transcutaneous electrical nerve stimulation (TENS) devices, which provide electric currents to the nerves to stimulate them for therapeutic purposes, have experienced a significant threat to revenue growth during the past five years. A 2012 Medicare decision to eliminate coverage of industry devices prescribed for chronic lower back pain dealt a severe blow to the industry, which relies on Medicare for a significant portion of its funding. As a result of this change, industry growth slowed considerably and is expected to remain subdued during the next five years. Average industry profit margins have fallen slightly during the five years to 2016, as companies have struggled to adjust to the changes in Medicare coverage and the imposition of a 2.3% medical device excise tax. However, profit margins will likely remain steady during the five years to 2021, due to industry costs stabilizing during this period.
This industry manufactures transcutaneous electrical nerve stimulation (TENS) devices. These machines provide electric currents to the nerves to stimulate them for therapeutic purposes, mainly for pain relief.
This report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors. Also included are five year industry forecasts, growth rates and an analysis of the industry key players and their market shares.